Ribomic

Ribomic Stock-Based Compensation

The Stock-Based Compensation (SBC) of Ribomic (4591.T) as of Nov 1, 2026 is 2.04 M JPY. In the previous year, Stock-Based Compensation (SBC) was 1.95 M JPY — a change of 4.61% (higher).

Stock-Based Compensation

2.04 MJPY

YoY

4.61%

Last updated:

Stock-Based Compensation (SBC) of Ribomic is 2026 2.04 M JPY. Stock-Based Compensation (SBC) of Ribomic was 2025 1.95 M JPY. It decreases by 4.61% higher compared to the previous year.

The Ribomic Stock-Based Compensation history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Stock-Based Compensation
Date
Stock-Based Compensation
Jan 1, 2021
0.00 JPY
Jan 1, 2022
3.11 M JPY
Jan 1, 2023
6.59 M JPY
Jan 1, 2024
6.26 M JPY
Jan 1, 2025
1.95 M JPY
Jan 1, 2026
2.04 M JPY
The Ribomic Stock-Based Compensation history
YEARStock-Based CompensationYoY
2.04 MJPY+4.61%
1.95 MJPY-68.85%
6.26 MJPY-5.00%
6.59 MJPY+111.96%
3.11 MJPY—
0.00JPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Ribomic Stock analysis

What does Ribomic do? Ribomic, Inc. engages in the research and development of molecular targeted drugs using Ribonucleic Acid (RNA) aptamers for therapeutic applications. Headquartered in Minato-Ku, Tokyo-To, the company utilizes its workforce of 25 full-time employees to drive its drug discovery operations, which are structured into self discovery and co-discovery divisions. This operational framework allows the firm to focus on advancing RNA aptamer technologies for medical use. The Self Drug Discovery division develops aptamers and licenses these results to pharmaceutical companies, generating revenue through intellectual property transfers. Meanwhile, the Co-Discovery division collaborates with alliance pharmaceutical companies researching aptamer pharmaceuticals. This segment earns research expenses paid by the alliance partners for the shared portion of the co-discovery business, creating a dual revenue stream based on licensing and collaborative research fees. Ribomic is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Ribomic stock

Stock-Based Compensation (SBC) of Ribomic is 2.04 M JPY in 2026.

Stock-Based Compensation (SBC) of Ribomic changed from 1.95 M JPY to 2.04 M JPY, representing a 4.61% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Stock-Based Compensation (SBC) Ribomic since 2006 – with annual values, charts, and detailed analysis.

Stock-based compensation is a non-cash expense representing equity awards to employees. High SBC can dilute existing shareholders and inflate reported cash flow.

Stock-Based Compensation (SBC)'s JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Stock-Based Compensation (SBC)'s Ribomic historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Ribomic

All Key Metrics — Ribomic